Barclays analyst Matt Miksic raised the firm’s price target on Insulet to $292 from $245 and keeps an Equal Weight rating on the shares. The Omnipod 5 launch continues to drive strong sales growth, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PODD:
- Insulet reports Q4 adjusted EPS 55c, consensus 21c
- DexCom selloff on Apple article should be bought, says Oppenheimer
- Insulet acquires assets of Automated Glucose Control for $25M
- Insulet acquires insulin pump patents from Bigfoot Biomedical for $25M
- Insulet initiated with a Peer Perform at Wolfe Research
